A study to evaluate the safety and efficacy of Vedolizumab for the treatment of inflammatory bowel disease in real world clinical practice

Trial Profile

A study to evaluate the safety and efficacy of Vedolizumab for the treatment of inflammatory bowel disease in real world clinical practice

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Oct 2016

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications Crohn's disease; Ulcerative colitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Oct 2016 Results (n=127) presented at the 24th United European Gastroenterology Week.
    • 07 Oct 2016 Results (n=127) published in the Alimentary Pharmacology and Therapeutics (2016).
    • 01 Apr 2016 Results (n=212) published in the Alimentary Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top